Place des traitements ciblés dans la prise en charge des cancers broncho-pulmonaires

Cancer du poumon, bilan initial. Collection Recommandations et référentiels, ouvrage collectif édité par l’INCA, juin 2011 ; Boulogne-Billancourt. Recommandations professionnelles, Cancer du poumon non à petites cellules, Formes localisées non opérables, localement avancées et métastatiques. Collection Recommandations et référentiels, INCA, septembre 2010 ; Boulogne-Billancourt. Non-small Cell Lung Cancer Collaborative Group, 1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials, Br Med J, 311, 899, 10.1136/bmj.311.7010.899 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Pao, 2011, New driver mutations in non-small-cell lung cancer, Lancet Oncol, 12, 175, 10.1016/S1470-2045(10)70087-5 Lam, 2011, Targeted therapy: an evolving world of lung cancer, Respirology, 16, 13, 10.1111/j.1440-1843.2010.01821.x Jorissen, 2003, Epidermal growth factor receptor: mechanisms of activation and signalling, Exp Cell Res, 284, 31, 10.1016/S0014-4827(02)00098-8 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Pao, 2004, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci USA, 101, 11306, 10.1073/pnas.0405220101 D’addario, 2010, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v116, 10.1093/annonc/mdq189 Rosell, 2009, Screening for epidermal growth factor receptor mutations in lung cancer, New Engl J Med, 361, 958, 10.1056/NEJMoa0904554 Shigematsu, 2006, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int J Cancer, 118, 257, 10.1002/ijc.21496 Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer, J Clin Oncol, 21, 2237, 10.1200/JCO.2003.10.038 Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial, JAMA, 290, 2149, 10.1001/jama.290.16.2149 Perez-Soler, 2004, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer, J Clin Oncol, 22, 3238, 10.1200/JCO.2004.11.057 Hadoux, 2011, Cancers bronchiques des non-fumeurs: particularités épidémiologiques, thérapeutiques et moléculaires, Presse Med, 40, 371, 10.1016/j.lpm.2011.02.001 Giaccone, 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial-INTACT 1, J Clin Oncol, 22, 777, 10.1200/JCO.2004.08.001 Herbst, 2004, Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial – INTACT 2, J Clin Oncol, 22, 785, 10.1200/JCO.2004.07.215 Herbst, 2005, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol, 23, 5892, 10.1200/JCO.2005.02.840 Gatzemeier, 2007, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial, J Clin Oncol, 25, 1545, 10.1200/JCO.2005.05.1474 Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 Thatcher, 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), Lancet, 366, 1527, 10.1016/S0140-6736(05)67625-8 Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nature Rev Cancer, 7, 169, 10.1038/nrc2088 Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 Maruyama, 2008, Phase III study V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer, J Clin Oncol, 26, 4244, 10.1200/JCO.2007.15.0185 Kim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016/S0140-6736(08)61758-4 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, New Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Yang, 2010, Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS), Ann Oncol, 21, viii1, 10.1093/annonc/mdv513.01 Lee, 2009, A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung, J Thorac Oncol, 4, S283 Keedy, 2011, American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy, J Clin Oncol, 29, 2121, 10.1200/JCO.2010.31.8923 Ettinger, 2010, Non-small cell lung cancer, J Natl Comp Canc Netw, 8, 740, 10.6004/jnccn.2010.0056 Felip, 2011, Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010, Ann Oncol, 22, 1507, 10.1093/annonc/mdr150 Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, New Engl J Med, 362, 2380, 10.1056/NEJMoa0909530 Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X Rosell, 2011, Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial, J Clin Oncol, 29, 7503, 10.1200/jco.2011.29.15_suppl.7503 Landi, 2011, Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR, Nat Rev Clin Oncol, 8, 571, 10.1038/nrclinonc.2011.135 Ku GY, Haaland BA, De Lima Lopes G. Geftinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer 2011; Published online May 10. Besse, 2011, Quelle séquence de traitement chez les patients EGFR mutés ?, Rev Pneumol Clin, 67, S24, 10.1016/S0761-8417(11)70007-4 Azzoli, 2009, American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer, J Clin Oncol, 27, 6251, 10.1200/JCO.2009.23.5622 Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet 2011; Published online May 11. Bria, 2011, Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis, Ann Oncol, 22, 2277, 10.1093/annonc/mdq742 Gridelli, 2010, International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial, J Clin Oncol, 28, 7508, 10.1200/jco.2010.28.15_suppl.7508 Novello, 2011, Maintenance therapy in NSCLC: Why?. To whom?. Which agent?, J Exp Clin Cancer Res, 30, 50, 10.1186/1756-9966-30-50 Perol, 2011, Traitement de maintenance dans les cancers bronchiques non à petites cellules métastatiques: une révolution conceptuelle?, Presse Med, 40, 404, 10.1016/j.lpm.2011.01.009 Kim, 2011, Maintenance chemotherapy for non-small-cell lung cancer, Cancer Treat Rev, 37, 505, 10.1016/j.ctrv.2010.12.007 Gaafar, 2010, A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03), J Clin Oncol, 28, 7518, 10.1200/jco.2010.28.15_suppl.7518 Cappuzzo, 2010, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 11, 521, 10.1016/S1470-2045(10)70112-1 Perol, 2010, Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study, J Clin Oncol, 28, 7507, 10.1200/jco.2010.28.15_suppl.7507 Kabbinavar, 2010, J Clin Oncol, 28, 7526, 10.1200/jco.2010.28.15_suppl.7526 Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from arandomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small cell lung cancer, J Clin Oncol, 29, 4113, 10.1200/JCO.2010.31.8162 Des Guetz, 2011, Is there a benefit to maintenance therapy after first-line chemotherapy in advanced non-small cell lung cancer - a systematic review with meta-analysis, Eur J Cancer, 47, 9005 Pirker, 2011, Monoclonal antibodies against EGFR in non-small cell lung cancer, Crit Rev Oncol Hematol, 80, 1, 10.1016/j.critrevonc.2010.10.008 Kelly, 2008, Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor, J Thorac Oncol, 3, 664, 10.1097/JTO.0b013e3181758141 Butts, 2007, Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 25, 5777, 10.1200/JCO.2007.13.0856 Rosell, 2008, Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer, Ann Oncol, 19, 362, 10.1093/annonc/mdm474 Lynch, 2010, Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099, J Clin Oncol, 28, 911, 10.1200/JCO.2009.21.9618 Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9 Chen, 2011, EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis, Eur J Clin Pharmacol, 67, 235, 10.1007/s00228-010-0965-4 Ibrahim, 2011, Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials, Lung, 189, 193, 10.1007/s00408-011-9286-3 Perez-Soler, 2006, Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer, Clin Lung Cancer, 8, S7, 10.3816/CLC.2006.s.008 Von Pawel, 2011, First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study, Lancet Oncol, 12, 30, 10.1016/S1470-2045(10)70278-3 Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 Allegra, 2009, American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy, J Clin Oncol, 27, 2091, 10.1200/JCO.2009.21.9170 O’byrne, 2011, Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study, Lancet Oncol, 12, 795, 10.1016/S1470-2045(11)70189-9 O’byrne, 2011, Epidermal growth factor receptor (EGFR) expression as a predictive biomarker of survival in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line therapy with cetuximab combined with chemotherapy in the FLEX trial, Eur J Cancer, 47, 9000 Von Pawel, 2011, Eur J Cancer, 47, 9019 Choong, 2008, trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer, J Thorac Oncol, 3, 1003, 10.1097/JTO.0b013e31818396a4 Stinchcombe, 2008, J Thorac Oncol, 3, 250, 10.1097/JTO.0b013e3181653cf4 Kelly, 2008, Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023, J Clin Oncol, 26, 2450, 10.1200/JCO.2007.14.4824 Bonner, 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 354, 567, 10.1056/NEJMoa053422 Hughes, 2008, A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study, J Thorac Oncol, 3, 648, 10.1097/JTO.0b013e3181757a60 Jatoi, 2010, A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422), Ann Oncol, 21, 2040, 10.1093/annonc/mdq075 Hallqvist, 2011, Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite-a phase II study from the Swedish Lung Cancer Study Group, Lung Cancer, 71, 166, 10.1016/j.lungcan.2010.05.011 Jensen, 2011, Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial, Cancer, 117, 2986, 10.1002/cncr.25888 Tredaniel, 2011, Etude de phase II évaluant l’association de cétuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pémétrexed dans le traitement des cancers bronchiques non à petites cellules non-épidermoides de stade III, inopérables, Rev Mal Respir, 28, 51, 10.1016/j.rmr.2010.06.027 Blumenschein, 2011, Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324, J Clin Oncol, 29, 2312, 10.1200/JCO.2010.31.7875 Govindan, 2011, Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407, J Clin Oncol, 29, 3120, 10.1200/JCO.2010.33.4979 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 Sandler, 2009, Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab, J Clin Oncol, 27, 1405, 10.1200/JCO.2008.16.2412 Socinski, 2009, Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases, J Clin Oncol, 27, 5255, 10.1200/JCO.2009.22.0616 De Braganca, 2010, Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer, J Neurooncol, 100, 443, 10.1007/s11060-010-0200-2 Reck, 2009, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466 Reck, 2010, Overall survival with cisplatin – gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Ann Oncol, 21, 1804, 10.1093/annonc/mdq020 Leighl, 2010, Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL), J Thorac Oncol, 5, 1970, 10.1097/JTO.0b013e3181f49c22 Crino, 2010, Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL MO19390): a phase 4 study, Lancet Oncol, 11, 733, 10.1016/S1470-2045(10)70151-0 Herbst, 2011, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial, Lancet, 377, 1846, 10.1016/S0140-6736(11)60545-X Spigel, 2009, Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer, J Thorac Oncol, 4, 1555, 10.1097/JTO.0b013e3181bbc540 Horn, 2009, Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501, J Clin Oncol, 27, 6006, 10.1200/JCO.2009.23.7545 Spigel, 2011, Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial, J Clin Oncol, 29, 2215, 10.1200/JCO.2010.29.3423 Kwak, 2010, Anaplastic Lymphoma Kinase inhibition in non–small-cell lung cancer, New Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Janku, 2010, Targeted therapy in non-small-cell lung cancer--is it becoming a reality?, Nat Rev Clin Oncol, 7, 401, 10.1038/nrclinonc.2010.64